Semnur Pharmaceuticals Inc's Comment on Sales, Marketing and Customers
The company focuses on the market for back pain treatment, specifically targeting sciatica and low back pain, conditions often treated with opioid prescriptions. Its product, SP-102, is positioned to become the first FDA-approved epidural steroid injection (ESI) for sciatica. The company intends to expand its portfolio with non-opioid therapeutics for pain management through research and development and strategic partnerships. Commercialization will leverage the infrastructure and sales force of its parent company, Scilex, which has experience launching non-opioid pain management products and maintains relationships with over 6,000 pain specialists, neurologists, and select healthcare providers. Scilex's existing products, including ZTlido, have established connections with physician audiences relevant to SP-102.
Semnur Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers
The company focuses on the market for back pain treatment, specifically targeting sciatica and low back pain, conditions often treated with opioid prescriptions. Its product, SP-102, is positioned to become the first FDA-approved epidural steroid injection (ESI) for sciatica. The company intends to expand its portfolio with non-opioid therapeutics for pain management through research and development and strategic partnerships. Commercialization will leverage the infrastructure and sales force of its parent company, Scilex, which has experience launching non-opioid pain management products and maintains relationships with over 6,000 pain specialists, neurologists, and select healthcare providers. Scilex's existing products, including ZTlido, have established connections with physician audiences relevant to SP-102.
Sources:
Semnur Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Semnur Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Semnur Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
